Bicara Therapeutics Inc.
BCAX
$14.81
$0.271.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 102.34% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 106.55% | -- | -- | -- | |
| Operating Income | -106.55% | -- | -- | -- | |
| Income Before Tax | -30.45% | -- | -- | -- | |
| Income Tax Expenses | 3,640.00% | -- | -- | -- | |
| Earnings from Continuing Operations | -30.80% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -30.80% | -- | -- | -- | |
| EBIT | -106.55% | -- | -- | -- | |
| EBITDA | -106.50% | -- | -- | -- | |
| EPS Basic | 54.63% | -- | -- | -- | |
| Normalized Basic EPS | 54.63% | -- | -- | -- | |
| EPS Diluted | 54.63% | -- | -- | -- | |
| Normalized Diluted EPS | 54.63% | -- | -- | -- | |
| Average Basic Shares Outstanding | 2,782.49% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 2,782.49% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |